R.Yu. ILYINA¹, R.G. KARIMOVA², L.R. MUKHAMEDZHANOVA³, L.E. ZIGANSHINA⁴

¹ Kazan State Medical Academy — Branch Campus of the RMACPE MOH Russia, 36 Butlerov Str., Kazan, Russian Federation, 420012

²Kazan State Academy of Veterinary Medicine named after N.A. Bauman, 35 Sibirskiy Trakt, Kazan, Russian Federation, 420029

³Chuvash State University named after N.I. Ulyanov, 15 Moskovskiy prospekt, Cheboksary, Russian Federation, 428015

⁴Kazan (Volga) Federal University, 18 Kremlevskaya Str., Kazan, Russian Federation, 420008

 Ilyina R.Y. — Cand. Med. Sc., Associate Professor of the Department of Maxillofacial Surgery and Surgical Stomatology, tel. +7-917-255-43-87, e-mail: [email protected]

Karimova R.G. — D. Med. Sc., Professor, Head of the Department of Physiology and Pathological Physiology, tel. +7-917-255-43-87, e-mail: [email protected]

Mukhamedzhanova L.R. — D. Med. Sc., Professor of the Department of Propedeutics of Stomatology Diseases and New Technologies, tel. +7-965-597-11-64, e-mail: [email protected]

Ziganshina L.E. — D. Med. Sc., Professor, Head of the Department of Experimental and Clinical Pharmacology, tel. +7-917-255-43-87, e-mail: lezign@gmail.com

 The article presents the results of an experiment on adult Vistar rats, who took haloperidol in therapeutic doses (intraperitoneal) and dimephosphonum with xydifon (per os) during 90 days. Prior and after the experiment, levels of total calcium and alkaline phosphatase in blood serum and oxyproline in urine were determined. Postmortal X-ray of the spine bone was carried out. The analysis of the experiment showed the reduction of alkaline phosphatase and oxyproline levels in rats, who took haloperidol together with dimephosphonum and xydifon; reduction of levels of total calcium (in comparison with rats on the monotherapy of haloperidol). In 30% of rats who took a neuroleptic drug, pathologic fractures, thinning of cortical lamina, foci of subcortical osteoporosis and clearing zones in the spongeous bone were found with roentgen research. Conclusions were made about an expressed osteoporosis-induction effect of haloperidol therapeutic doses in rats, as well as the positive influence of dimephosphonum and xydifon on bone tissue metabolism in experiment on rats.

Key words: experimental osteoporosis, haloperidol, dimephosphonum, xydifon.

REFERENCES

1. Mutică M., Marinescu I., Militaru F., Pîrlog M.C., Udriştoiu I. Clinical and biological outcomes of prolonged treatment with haloperidol in schizophrenia. Rom J Morphol Embryol, 2016, no. 57(2), pp. 477-81.
2. Katherine J., Ingrid Dick-de-Paula Trabecular bone loss after administration of the second generation antipsychotic risperidone is independent of weight gain. Bone, 2012, no. 50(2), pp. 490–498.
3. Valeeva I.H., Titarenko A.F., Ziganshina L.E. Sravnitel’noe izuchenie jeffektivnosti dimefosfona i ksidifona pri indometacin-inducirovannoj gastropatii u krys [Comparative study efficiency of dimephosphonum and xydifon with indometacin-induce gastropathology in rats]. Experimental and clinic pharmacology, 2010, no. 73(12), pp. 21-24.
4. Malyshev V.G., Fedosejkin I.V. Primenenie dimefosfona v medicine [Application of dimephosphonum in medicine], 2008, pp. 84-85.
5. Burnasheva Z.A., Ziganshina L.E., Salihov I.G., Valeeva I.H. Mineral’nyj obmen pri modelirovanii steroidnogo osteoporoza i ego korrekcija dimefosfonom [Mineral metabolism in experimental osteoporosis and him correction by dimephosphonum]. Human and medicine: Russian national congress, 1998, pp. 24-56.
6. Valeeva I.H., Titarenko A.F., Haziahmetova V.N., Ziganshina L.E. Dimefosfon projavljaet protivovospalitel’nuju i antioksidantnuju aktivnost’ na modeli hronicheskogo autoimmunnogo vospalenija [Dimephosphonum shows anti-inflammatory and antioxidant activity in the modal of chronic inflammatory]. Jeksperiment. i klinich. Farmakologija, 2008, no. 74(3) pp. 6-13.
7. Ziganshina L.E., Studencova I.A., Zaikonnikova I.V. i dr. Vlijanie dimefosfona na processy jekssudacii i proliferacii [Dimephosphonum influence on the process of acssudation and proliferation ]. Farmakologija i toksikologija, 1999, no. 53(1), pp. 57-59.
8. Riggz Lorens B., Melton Dzhozef L. Osteoporoz. Jetiologija, diagnostika, lechenie. – [Osteoporosis — etiology, diagnostics and treatment], 2000, pp. 278-283.
9. Hummer M., Malik P., Rudolf W., M.D. and at all. Osteoporosis in patients with schizophrenia. American J of Psychiatry, 2005, no. 162, pp.162-167.
10. Ershova A.K. O primenenii preparata ksidifon pri narushenii kal’cievogo obmena [Appliances of xydifon in disturbance calcium metabolism]. Rossijskij medicinskij zhurnal, 2010, no. 18(14), pp. 884-886.